At present, its use could be justified as initial anticoagulation therapy, both for prophylaxis and treatment of thromboembolic disease, replacing unfractioned heparin. In addition, it should not be used for more than ten days. The potential benefits would be shorter hospital stay, fewer laboratory controls and easiness of administration.